Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery

Journal of Chemical Information and Computer Sciences

Volumn 41, Issue 3, 2001, Pages 856-864

  Hann, Michael M ^a   Leach, Andrew R ^a   Harper, Gavin ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG RECEPTOR; LIGAND;

CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; DRUG SCREENING; REVIEW;

DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; LIGANDS; MODELS, MOLECULAR; RECEPTORS, DRUG;

MOLECULAR COMPLEXITY;

DRUG INTERACTIONS; DRUG PRODUCTS; ENTHALPY; ENTROPY; FREE ENERGY; MOLECULES; OPTIMIZATION; PROBABILITY;

MOLECULAR PHYSICS;

EID: 0035324944     PISSN: 00952338     EISSN: None     Source Type: Journal    
DOI: 10.1021/ci000403i     Document Type: Article

References (32)

1. Hird, N. Isn't combinatorial chemistry just chemistry? Drug Discovery Today 2000, 5(8), 307-308.
2. Leach, A. R.; Hann, M. M. The in silico world of virtual libraries. Drug Discovery Today 2000, 5(8), 326-336.
3. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997, 23(1-3), 3-25.
4. Sadowski, J.; Kubinyi, H.. A scoring scheme for discriminating between drugs and nondrugs. J. Med. Chem. 1998, 41(18), 3325-3329
5. Gillet, V. J.; Willett, P.; Bradshaw, J.; Green, D. V. S. Selecting Combinatorial Libraries to Optimize Diversity and Physical Properties. J. Chem. Inf. Comput. Sci. 1999, 39(1), 169-177.
6. Teague, S. J.; Davis, A. M.; Leeson, P. D.; Oprea, T. The design of leadlike combinatorial libraries. Angew. Chem., Int. Ed. Engl. 1999, 38(24), 3743-3748.
7. Leach, A. R. Molecular Modeling; Principles and Applications; Longmans: 1996; pp 480-541.
8. Andrews, P. R.; Craik, D. J.; Martin, J. L. Functional group contributions to drug-receptor interactions. J. Med. Chem. 1984, 27-(12), 1648-57.
9. Williams, D. H.; Westwell, M. S. Aspects of weak interactions. Chem. Soc. Rev. 1998, 27(1), 57-64.
10. Bissantz, C.; Folkers, G.; Rognan, D. Protein-Based Virtual Screening of Chemical Databases. 1. Evaluation of Different Docking/Scoring Combinations. J. Med. Chem. 2000, 43(25), 4759-4767.
11. Hopfinger, A. J.; Wang, S.; Tokarski, J. S.; Jin, B.; Albuquerque, M.; Madhav, P. J.; Duraiswami, C. Construction of 3D-QSAR Models Using the 4D-QSAR Analysis Formalism. J. Am. Chem. Soc. 1997, 119(43), 10509-10524.
12. (b) Venkatarangan, P.; Hopfinger, A. J. Prediction of Ligand-Receptor Binding Free Energy by 4D-QSAR Analysis: Application to a Set of Glucose Analogue Inhibitors of Glycogen Phosphorylase. J. Chem. Inf. Comput. Sci. 1999, 39(6), 1141-1150.
13. Mason, J. S.; Morize, I.; Menard, P. R.; Cheney, D. L.; Hulme, C.; Labaudiniere, R. F. New 4-Point Pharmacophore Method for Molecular Similarity and Diversity Applications: Overview of the Method and Applications, Including a Novel Approach to the Design of Combinatorial Libraries Containing Privileged Substructures. J. Med. Chem. 1999, 42(17), 3251-3264.
14. Rejto, P. A.; Verkhivker, G. M. Unraveling principles of lead discovery: From unfrustrated energy landscapes to novel molecular anchors. Proc. Natl. Acad. Sci. U.S.A. 1996, 93(17), 8945-8950.
15. A tanh function was used to create this shape of curve.
16. Cochran, A. G. Antagonists of protein-protein interactions. Chem. Biol. 2000, 7(4), R85-R94.
17. Sneader, W. Drug Prototypes and their Exploitation; John Wiley and Sons Ltd.: 1996.
18. Daylight theory manual and related documentation available at http:// www.daylight.com/dayhtml/doc/theory/theory.toc.html.
19. Analysis showed these natural product derived compounds to have a much wider distribution of properties and changes on going from lead to drug, reflecting that natural products provide a different (but effective way) in which drugs have been developed. The fact that natural products have been arrived at over many millennia of evolution suggest that considerable optimisation of interactions with related biotargets has already be embedded in the leads that we have then been found via screening.
20. Leach, A. R.; Bradshaw, J.; Green, D. V. S.; Hann, M. M.; Delany, J. J., III. Implementation of a System for Reagent Selection and Library Enumeration, Profiling, and Design. J. Chem. Inf. Comput. Sci. 1999, 39(6), 1161-1172.
21. World Drug Index published by Derwent available from Daylight Inc.
22. Calculated logP as calculated by PC-models module from Daylight Inc; http://www.daylight.com/.
23. Number of aromatic rings calculated using Daylight toolkit.
24. Andrew's binding energy calculated via in-house routines based on ref8.
25. Number of bits set on in the standard 1024 Daylight fingerprint. This reflects the number of different atoms and bond connection within a molecule and is therefore a useful measure of the internal complexity of a molecule.
26. Calculated Molecular Refractivity (CMR) as calculated by PC-models module from Daylight Inc; http://www.daylight.com/.
27. Conti, E.; Rivetti, C.; Wonacott, A and Brick, P. X-ray and spectrophotomeric studies of the binding of proflavin to the S1 specificity pocket of human thrombin. FEBS Lett. 1998, 425, 229-233.
28. Coote, S. J.; Dowle, M. D.; Finch, H.; Hann, M. M.; Kelly, H. A.; MacDonald, S. J. F.; Pegg, N. A.; Ramsden, N. G.; Watson, N. S.. Furopyrrolidine derivatives and their use as serine protease inhibitors. PCT Int. Appl. 1999, WO 9912936.
29. Pass, M.; Abu-Rabie, S.; Baxter, A.; Conroy, R.; Coote, S. J.; Craven, A. P.; Finch, H.; Hindley, S.; Kelly, H. A.; Lowdon, A. W.; McDonald, E.; Mitchell, W. L.; Pegg, N. A.; Procopiou, P. A.; Ramsden, N. G.; Thomas, R.; Walker, D. A.; Watson, N. S.; Jhoti, H.; Mooney, C. J.; Tang, C.; Thomas, P. J.; Parry, S.; Patel, C. Thrombin inhibitors based on [5,5] trans-fused Indane lactams. Bioorg. Med. Chem. Lett. 1999, 9(12), 1657-1662.
30. Hajduk, P. J.; Meadows, R. P.; Fesik, S. W.. Discovering high-affinity ligands for proteins. Science 1997, 278(5337), 497-499.
31. Maly, D. J.; Choong, I. C.; Ellman, J. A.. Combinatorial target-guided ligand assembly: identification of potent subtype-selective c-Src inhibitors. Proc. Natl. Acad. Sci. U.S.A. 2000, 97(6), 2419-2424.
32. Boehm, H.-J.; Boehringer, M.; Bur, D.; Gmuender, H.; Huber, W.; Klaus, W.; Kostrewa, D.; Kuehne, H.; Luebbers, T.; Meunier-Keller N.; Mueller, F. Novel Inhibitors of DNA Gyrase: 3D Structure Based Biased Needle Screening, Hit Validation by Biophysical Methods, and 3D Guided Optimization. A Promising Alternative to Random Screening. J. Med. Chem. 2000, 43(14), 2664-2674.